Business Context and Reporting Period
Company: Cardinal Health, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 14, 2025
Subject: Regulation FD Disclosure regarding an update to fiscal year 2025 non-GAAP earnings per share (EPS) expectations.
Key Financial Metrics
Non-GAAP EPS Guidance (Fiscal Year 2025): The Company now expects results to be toward the high end of its previously provided range of $7.75 to $7.90.
GAAP Guidance: The Company does not provide forward-looking guidance on a GAAP basis.
Other Metrics: The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity for the current period.
Material Changes
- Guidance Revision: Management has updated its outlook for fiscal year 2025 non-GAAP EPS, indicating performance is expected to be at the high end of the prior range ($7.75 to $7.90).
- Driver: The improvement is primarily driven by continued strength within the Pharmaceutical and Specialty Solutions segment.
Outlook, Risks, and Management Commentary
Management Commentary: The update was announced in conjunction with a presentation at the JP Morgan 43rd Annual Healthcare Conference on January 14, 2025. Further details on fiscal year 2025 expectations are expected on the second quarter earnings call on January 30, 2025.
Risks and Contingencies: Forward-looking statements are subject to significant risks, including:
- Execution of the GMPD Improvement Plan and potential impacts from Cardinal Health Brand sales.
- Ongoing inflationary pressures and possible tariffs on sourced or manufactured products.
- Competitive pressures and potential contract terminations or non-renewals by customers.
- Uncertainties in branded pharmaceutical pricing due to possible legislative action.
- Litigation risks, specifically a Department of Justice investigation regarding potential violations of the Anti-Kickback Statute and False Claims Act.
- External events such as weather or geopolitical issues affecting supply and demand.
- Performance of the generics program, including generic deflation rates.
- Potential impairment of At-Home unit goodwill due to changes in financial plans, interest rates, or tax rates.
Investor Verification Checklist
- Verify the specific non-GAAP EPS figure expected at the "high end" of the $7.75 to $7.90 range during the January 30, 2025 earnings call.
- Review the reconciliation of non-GAAP financial measures to GAAP measures on the Investor Relations website.
- Monitor updates regarding the Department of Justice investigation into Anti-Kickback Statute and False Claims Act violations.
- Assess the impact of the GMPD Improvement Plan execution on future margins.
- Track legislative developments affecting branded pharmaceutical pricing.